Cytokine-Secreting CAR T-Cell Candidate Therapy Shows Preliminary Efficacy in Patients with Lymphoma

A next-generation CAR T cell therapy showed promising results in patients whose B-cell lymphomas continued to resist multiple rounds of other cancer treatments, including commercially available CAR T cell therapies. Jakub Svoboda, MD, an associate professor of Hematology-Oncology, Carl June, MD, the Richard W. Vague Professor in Immunotherapy, and Penn colleagues published the clinical trial results in the New England Journal of Medicine in May.